DUAL II China: Superior HbA1c reductions and weight loss with insulin degludec/liraglutide (IDegLira) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin,Diabetes, Obesity and Metabolism

当前位置： X-MOL 学术 › Diabetes Obes. Metab. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

DUAL II China: Superior HbA1c reductions and weight loss with insulin degludec/liraglutide (IDegLira) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin
Diabetes, Obesity and Metabolism ( IF 5.4 ) Pub Date : 2021-08-13 , DOI: 10.1111/dom.14522
Yu Pei ₁ , Bue R. Agner ₂ , Bin Luo ₃ , Xiaolin Dong ₄ , Dongmei Li ₅ , Jun Liu ₆ , Lei Liu ₇ , Ming Liu ₈ , Yibing Lu ₉ , Tomoyuki Nishida ₁₀ , Xiangjin Xu ₁₁ , Yiming Mu ₁

Affiliation

To assess the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin degludec (degludec) in Chinese people with type 2 diabetes (T2D) treated with basal insulin.

更新日期：2021-08-13

点击分享查看原文

点击收藏

阅读更多本刊最新论文